Page 347 - Glucose Monitoring Devices

354 CHAPTER 16 The dawn of automated insulin delivery

[90] Tauschmann M, Allen JM, Nagl K, Fritsch M, Yong J, Metcalfe E, et al. Home use of
day-and-night hybrid closed-loop insulin delivery in very young children: a multi-
center, 3-week, randomized trial. Diabetes Care 2019;42(4):594e600.
[91] de Bock M, Dart J, Hancock M, Smith G, Davis EA, Jones TW. Performance of
medtronic hybrid closed-loop iterations: results from a randomized trial in adolescents
with type 1 diabetes. Diabetes Technology and Therapeutics 2018;20(10):693e7.
[92] DeBoer MD, Breton MD, Wakeman C, Schertz EM, Emory EG, Robic JL, et al.
Performance of an artificial pancreas system for young children with type 1
diabetes. Diabetes Technology and Therapeutics 2017;19(5):293e8.
[93] Tauschmann M, Allen JM, Wilinska ME, Thabit H, Stewart Z, Cheng P, et al. Day-and-
night hybrid closed-loop insulin delivery in adolescents with type 1 diabetes: a
free-living, randomized clinical trial. Diabetes Care 2016;39(7):1168e74.
[94] Spaic T, Driscoll M, Raghinaru D, Buckingham BA, Wilson DM, Clinton P, et al.
Predictive hyperglycemia and hypoglycemia minimization: in-home evaluation of
safety, feasibility, and efficacy in overnight glucose control in type 1 diabetes. Diabetes
Care 2017;40(3):359e66.
[95] Thabit H, Elleri D, Leelarathna L, Allen J, Lubina-Solomon A, Stadler M, et al.
Unsupervised overnight closed loop insulin delivery during free living: analysis of
randomised cross-over home studies in adults and adolescents with type 1 diabetes.
Lancet 2015;385(Suppl. 1):S96.
[96] Thabit H, Elleri D, Leelarathna L, Allen JM, Lubina-Solomon A, Stadler M, et al.
Unsupervised home use of an overnight closed-loop system over 3e4 weeks: a pooled
analysis of randomized controlled studies in adults and adolescents with type 1
diabetes. Diabetes, Obesity and Metabolism 2015;17(5):452e8.
[97] Blauw H, van Bon A, Koops R, DeVries J. Performance and safety of an integrated
bihormonal artificial pancreas for fully automated glucose control at home. Diabetes,
Obesity and Metabolism 2016;18(7):671e7.
[98] Del Favero S, Bruttomesso D, Di Palma F, Lanzola G, Visentin R, Filippi A, et al. First
use of model predictive control in outpatient wearable artificial pancreas. Diabetes
Care 2014;37(5):1212e5.
[99] Bergenstal RM, Garg S, Weinzimer SA, Buckingham BA, Bode BW, Tamborlane WV,
et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1
diabetes. Journal of the American Medical Association 2016;316(13):1407e8.
[100] Garg SK, Weinzimer SA, Tamborlane WV, Buckingham BA, Bode BW, Bailey TS,
et al. Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery
system in adolescents and adults with type 1 diabetes. Diabetes Technology and Ther-
apeutics 2017;19(3):155e63.
[101] Lee SWSJ, Coredero T, Kaufman F. Glycemic outcomes during MiniMed 670G
system use in children aged 2e6 years with type 1 diabetes. Berlin, Germany:
Advanced Technologies and Treatments forr Diabetes Conference; 2019.
[102] Christiansen MP, Garg SK, Brazg R, Bode BW, Bailey TS, Slover RH, et al. Accuracy
of a fourth-generation subcutaneous continuous glucose sensor. Diabetes Technology
and Therapeutics 2017;19(8):446e56.
[103] Slover RH, Tryggestad JB, DiMeglio LA, Fox LA, Bode BW, Bailey TS, et al.
Accuracy of a fourth-generation continuous glucose monitoring system in children
and adolescents with type 1 diabetes. Diabetes Technology and Therapeutics 2018;
20(9):576e84.